Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by EbbFlow88on Dec 15, 2022 11:16am
235 Views
Post# 35173259

Depreciation/Amortization

Depreciation/AmortizationCan anyone speak to the amount of D&A we're expensing. I can't seem to find any info on amortizing our intangibles and how aggressive it is. There's a lot lumped into the 370K intagible book value and we're amortizing about 45K/Year so about 12% or roughly an average life of 8 years. 

That would seem aggressive to me, which would currently keep operations showing little profits so paying less tax, while piling our cash from operations back into stock buybacks and product acquisitions. 

It would seem that we're "hiding or muting" current profitability in the short run but will have a huge ramp up later as the product life is longer than 8 years on average. 

As an example, Exelon product life will likely be longer than 8 years but will be fully amortized, so any sales would go right to net operating profit.

Am I seeing this correctly? Has anyone had experience with this during Paladin years or just in general? Thanks!


<< Previous
Bullboard Posts
Next >>